![Luca Gianni](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Oorsprong van het eerstegraads netwerk van Luca Gianni
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
SynAffix BV
![]() SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands.
7
| Subsidiary | Biotechnology | 7 |
Targovax Oy
![]() Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland.
5
| Subsidiary | Pharmaceuticals: Major | 5 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Luca Gianni via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
Genentech, Inc.
![]() Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member | |
BIOGEN INC. | Pharmaceuticals: Major | Sales & Marketing | |
CUBIST PHARMACEUTICALS INC | Pharmaceuticals: Major | Chief Operating Officer | |
Sandoz, Inc.
![]() Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Mylan, Inc.
![]() Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Micreos BV
![]() Micreos BV Pharmaceuticals: GenericHealth Technology Micreos BV develops phage-based products against specific dangerous bacteria. It offers human health, food safety, agriculture and animal health products. The company was founded by Mark Offerhaus and is headquartered in Wageningen, the Netherlands. | Pharmaceuticals: Generic | Chairman | |
SQZ BIOTECHNOLOGIES COMPANY | Biotechnology | Director/Board Member | |
Corob Oy
![]() Corob Oy Industrial SpecialtiesProcess Industries Corob Oy supplies color tinting systems. It offers complete tinting solutions: CPSCOLOR TM colorants (liquid pigments), COROB TM dispensing and mixing/shaking equipment, software, color marketing tools, customer support and service. The firm serves paint manufacturers, retail chains, leather and plastics producers. The company was founded in 2000 and is headquartered in Pori, Finland. | Industrial Specialties | Sales & Marketing | |
Karolinska Institutet | College/University | Corporate Officer/Principal | |
Technische Universiteit Eindhoven | College/University | Undergraduate Degree | |
SANTHERA PHARMACEUTICALS HOLDING AG | Pharmaceuticals: Major | Director/Board Member | |
University of London | College/University | Masters Business Admin | |
The University of Edinburgh | College/University | Doctorate Degree | |
King's College (Pennsylvania) | College/University | Corporate Officer/Principal | |
The University of Sydney | College/University | Graduate Degree | |
University of Leiden | College/University | Doctorate Degree Doctorate Degree | |
Radboud University Nijmegen | College/University | Corporate Officer/Principal Graduate Degree | |
National & Kapodistrian University of Athens | College/University | Graduate Degree | |
University of Helsinki | College/University | Corporate Officer/Principal Doctorate Degree | |
University of Strasbourg | College/University | Doctorate Degree | |
Forbion Capital Partners Management Holding BV
![]() Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor | |
The Royal College of Physicians | College/University | Corporate Officer/Principal | |
F2G Ltd.
![]() F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
Acacia Pharma Ltd.
![]() Acacia Pharma Ltd. Pharmaceuticals: MajorHealth Technology Acacia Pharma Ltd. develops supportive care product opportunities for post-surgical and cancer patients. It specializes in the discovery and development of cancer supportive care product opportunities based on established drugs. The firm’s product pipeline addresses supportive care indications, such as post-operative and chemotherapy-induced nausea and vomiting, xerostomia and cachexia. The company was founded by Andrew Muncey, Julian Clive Gilbert and Robert William Gristwood in 2006 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
Glaxo, Inc. | Corporate Officer/Principal | ||
BiognoSYS AG
![]() BiognoSYS AG Packaged SoftwareTechnology Services BiognoSYS AG operates as a biotechnology company. Its products include iRT Kit, HRM Kit, Sample Prep Kit, PlasmaDive, Spectronaut and SpectroDive. The company was founded by Philipp M. Antoni, Johan Malmstroem and Oliver Rinner on September 3, 2008 and is headquartered in Schlieren, Switzerland. | Packaged Software | Chairman | |
Athyrium Capital Management LP
![]() Athyrium Capital Management LP Investment ManagersFinance Athyrium Capital Management LP (Athyrium) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Jeffrey A. Ferrell in 2008 as Athyrium Capital Management LLC and converted from a Delaware limited liability company to a Delaware limited partnership in 2015. Athyrium provides advisory services on a discretionary basis to its clients, which may include specific tailored vehicles and pooled investment vehicles intended for sophisticated investors and institutional investors. | Investment Managers | Consultant / Advisor | |
ARCH BIOPARTNERS INC. | Pharmaceuticals: Major | Director/Board Member | |
Epsilon-3 Bio Ltd
![]() Epsilon-3 Bio Ltd Pharmaceuticals: OtherHealth Technology Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Other | Founder | |
INHIBIKASE THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
CIRCIO HOLDING ASA | Biotechnology | Chairman Chief Tech/Sci/R&D Officer | |
SPERO THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Kellogg School of Management | College/University | Masters Business Admin | |
ADVANZ PHARMA CORP. LIMITED | Pharmaceuticals: Major | Director/Board Member | |
University of Rochester Simon Business School | College/University | Masters Business Admin | |
PIQUR Therapeutics AG
![]() PIQUR Therapeutics AG Pharmaceuticals: OtherHealth Technology PIQUR Therapeutics AG engages in development of anti-cancer drugs based on the inhibition. Its products include PQR309, PQR620 and PQR5xx. The company was founded by Bernd Giese, Vladimir Cmiljanovic, Andreas Emmenegger, Ralf Rosenow and Matthias Wymann in August 2011 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Other | Chairman | |
ACACIA PHARMA GROUP PLC | Pharmaceuticals: Other | Chairman | |
Amryt Pharma Holdings Ltd.
![]() Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
NMD Pharma A/S
![]() NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Biotechnology | Chairman | |
Essential Pharmaceuticals LLC
![]() Essential Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Part of Intas Pharmaceuticals Ltd., Essential Pharmaceuticals LLC is a company that manufactures and markets pharmaceutical products. The company is based in Durham, NC. The company was founded in 2006. Emma Jane Johnson has been the CEO of the company since 2023. Essential Pharmaceuticals was acquired by Accord Healthcare, Inc. on July 26, 2017. | Pharmaceuticals: Major | Chairman | |
Essential Pharmaceuticals Ltd.
![]() Essential Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Essential Pharmaceuticals Ltd. manufactures pharmaceutical products. The company was founded on November 24, 2010 and is headquartered in Egham, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
Gyrus Capital SA | Investment Managers | Private Equity Investor | |
AMRYT PHARMA PLC | Pharmaceuticals: Major | Director/Board Member | |
F2g Inc. | Director/Board Member |
Statistieken
Internationaal
Verenigde Staten | 19 |
Verenigd Koninkrijk | 13 |
Nederland | 6 |
Zwitserland | 5 |
Finland | 3 |
Sectoraal
Health Technology | 30 |
Consumer Services | 15 |
Finance | 4 |
Process Industries | 2 |
Technology Services | 2 |
Operationeel
Director/Board Member | 40 |
Corporate Officer/Principal | 22 |
Chairman | 17 |
Chief Tech/Sci/R&D Officer | 9 |
Graduate Degree | 7 |
Sterkste connecties
- Beurs
- Insiders
- Luca Gianni
- Bedrijfsconnecties